| Literature DB >> 31482084 |
Ying Fu1, Yong-Xuan Liu1, Ke-Han Yi1, Ming-Qiang Li1, Jia-Zhong Li2, Fei Ye1.
Abstract
4-Hydroxyphenylpyruvate dioxygenase (Entities:
Keywords: 4-hydroxyphenylpyruvate dioxygenase inhibitors; molecular docking; molecular dynamics; molecular mechanics Poisson–Boltzmann surface area; three-dimensional quantitative structure activity relationship
Year: 2019 PMID: 31482084 PMCID: PMC6710436 DOI: 10.3389/fchem.2019.00556
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Figure 1The computational workflow was applied.
Figure 2The chemical structure of DAS869, mesotrione, and compounds 01 and 02.
The structure of 2-(aryloxyacetyl)cyclohexane-1,3-diones derivatives and corresponding experimental and predicted activity.
| 01 | H | H | 5.906 | 5.923 | 5.954 | 5.962 | 6.007 |
| 02 | 5,5-diCH3 | H | 5.254 | 5.257 | 5.218 | 5.243 | 5.218 |
| 03 | H | 2-CH3 | 6.049 | 6.067 | 6.052 | 6.061 | 5.996 |
| 04 | 5,5-diCH3 | 2-CH3 | 5.797 | 5.806 | 5.810 | 5.774 | 5.774 |
| 05 | H | 3-CH3 | 6.206 | 6.266 | 6.236 | 6.443 | 6.643 |
| 06 | H | 4-CH3 | 6.005 | 5.979 | 5.992 | 5.969 | 6.005 |
| 07 | H | 4-OCH3 | 6.521 | 6.496 | 6.534 | 6.532 | 6.557 |
| 08 | H | 2-SCH3 | 6.223 | 6.218 | 6.242 | 6.237 | 6.216 |
| 09 | H | 2-Cl | 5.942 | 6.102 | 6.115 | 5.634 | 5.561 |
| 10 | 5,5-diCH3 | 2-Cl | 5.669 | 5.685 | 5.614 | 5.683 | 5.677 |
| 11 | H | 3-Cl | 7.125 | 7.105 | 7.078 | 7.042 | 7.142 |
| 12 | H | 4-Cl | 7.538 | 7.549 | 7.403 | 7.568 | 7.426 |
| 13 | H | 2-CF3 | 6.873 | 6.899 | 6.826 | 6.862 | 6.894 |
| 14 | H | 3-CF3 | 6.251 | 6.383 | 6.185 | 6.412 | 6.187 |
| 15 | H | 4-CF3 | 5.978 | 5.978 | 6.049 | 5.981 | 6.019 |
| 16 | H | 2-NO2 | 7.347 | 7.338 | 7.316 | 7.344 | 7.328 |
| 17 | H | 4-SO2CH3 | 6.451 | 6.448 | 6.404 | 6.481 | 6.419 |
| 18 | 5-CH3 | 4-SO2CH3 | 6.264 | 6.126 | 6.226 | 6.171 | 6.202 |
| 19 | H | 2,3-diCl | 6.947 | 6.939 | 7.006 | 6.959 | 6.949 |
| 20 | H | 2,4-diCl | 7.367 | 7.419 | 7.204 | 7.351 | 7.314 |
| 21 | H | 2,5-diCl | 6.917 | 6.895 | 6.976 | 6.954 | 6.884 |
| 22 | H | 2,6-diCl | 7.347 | 7.298 | 7.302 | 7.252 | 7.194 |
| 23 | H | 3,4-diCl | 6.573 | 6.562 | 6.553 | 6.576 | 6.624 |
| 24 | H | 3,5-diCl | 6.020 | 6.021 | 6.018 | 6.047 | 5.987 |
| 25 | 5-CH3 | 2,4-diCl | 6.706 | 6.687 | 6.708 | 6.728 | 6.723 |
| 26 | 5,5-diCH3 | 2,4-diCl | 5.318 | 5.154 | 5.254 | 5.123 | 5.788 |
| 27 | 4,4-diCH3 | 2,4-diCl | 6.616 | 6.599 | 6.576 | 6.629 | 6.628 |
| 28 | H | 2,4-diBr | 7.180 | 7.180 | 7.209 | 7.158 | 7.204 |
| 29 | 5,5-diCH3 | 2,4-diBr | 7.056 | 7.059 | 7.057 | 7.062 | 7.022 |
| 30 | H | 2-CH3-4-F | 6.682 | 6.693 | 6.773 | 6.701 | 6.64 |
| 31 | H | 2-CH3-4-Cl | 7.509 | 7.487 | 7.387 | 6.933 | 6.468 |
| 32 | 5-CH3 | 2-CH3-4-Cl | 7.432 | 7.386 | 7.476 | 7.451 | 7.493 |
| 33 | 5,5-diCH3 | 2-CH3-4-Cl | 6.959 | 6.965 | 6.935 | 6.932 | 6.932 |
| 34 | 4,4-diCH3 | 2-CH3-4-Cl | 5.699 | 5.612 | 5.715 | 5.375 | 5.364 |
| 35 | H | 2-CH3-4-Br | 7.108 | 7.154 | 7.229 | 7.081 | 7.164 |
| 36 | H | 2-CH3-4-NO2 | 7.114 | 7.130 | 7.145 | 7.093 | 7.113 |
| 37 | H | 2-Cl-4-F | 6.262 | 6.278 | 6.237 | 6.212 | 6.28 |
| 38 | H | 2-Cl-4-NO2 | 7.469 | 7.580 | 7.536 | 7.074 | 7.478 |
| 39 | H | 2-F-4-Cl | 6.455 | 6.439 | 6.516 | 6.428 | 6.438 |
| 40 | H | 2-NO2-3-CH3 | 7.161 | 7.149 | 7.166 | 7.197 | 7.185 |
| 41 | H | 3,5-diF-4-CN | 7.086 | 7.076 | 7.116 | 7.096 | 7.091 |
| 42 | H | 2,4,6-tri-Cl | 6.735 | 6.736 | 6.725 | 6.722 | 6.765 |
| 43 | H | 2,3,4,5,6-5F | 7.260 | 7.163 | 7.189 | 7.155 | 7.411 |
| Mesotrione | 7.886 | ||||||
Indicates the test set of compounds.
Results of CoMFA and CoMSIA models.
| 0.872 | 0.864 | 0.693 | 0.823 | |
| ONC | 10 | 10 | 10 | 10 |
| 0.999 | 0.990 | 0.998 | 0.995 | |
| SEE | 0.024 | 0.069 | 0.034 | 0.050 |
| 1776.949 | 215.356 | 898.323 | 425.569 | |
| 0.863 | 0.850 | 0.828 | 0.801 | |
| Steric | 52.3 | 9.4 | 83.4 | 9.7 |
| Electrostatic | 47.7 | 24.2 | 16.6 | 16.4 |
| Hydrophobic | – | 28.5 | – | 31.4 |
| Donor | – | 26.5 | – | 30.6 |
| Acceptor | – | 11.3 | – | 11.9 |
Indicates the statistical characteristics for the test set.
Figure 3The alignment of the molecules using (A) the common framework and (B) the docking simulation. Molecules are displayed in white for common C, red for O, blue for N, yellow for S, and green for F and Cl atoms, respectively. For a clear observation, hydrogen atoms are hidden.
Figure 4The plot of experimental and predicted activity based on the common framework (A,B) and molecular docking (C,D).
Figure 5CoMFAStDev*Coeff contour maps based on the common framework. (A) Steric contour map. Green and yellow contours show regions where steric bulk has favorable and unfavorable effects on the inhibition ability, respectively. (B) Electrostatic contour map. Blue contours indicate regions where electro-positive groups increase the activity, while white contours indicate regions that were electro-negative.
Figure 6(A) Steric and (B) electrostatic contours of the CoMFA from molecular docking.
Figure 7CoMSIAStDev*Coeff contour maps based on the common framework. (A) Steric contour map. (B) Electrostatic contour map. (C) Hydrophobic contour map. Yellow and white regions suggest the preference of hydrophobic groups and hydrophilic substitutions, respectively. (D) H-bond donor contour map. Cyan illustrates regions in which the introduction of a H-bond donor group is favored. Purple illustrates regions where the introduction of a H-bond donor group is disfavored. (E) H-bond acceptor contour map. Purple areas are the regions where H-bond acceptor is conducive to the activity; red areas are unfavorable.
Figure 8(A) Steric, (B) electrostatic, (C) hydrophobic, (D) H-bond donor, and (E) H-bond acceptor contours of the CoMSIA from molecular docking.
Figure 9Binding model of (A) compound 01, (B) compound 02, and (C) mesotrione.
Figure 10RMSD of (A) compound 01, (B) compound 02, and (C) mesotrione.
Binding free energy (kcal mol−1) of compounds 01 and 02 and mesotrione.
| Compound 01 | −26.48 (±2.49) | −92.50 (±6.88) | 102.45 (±3.64) | −3.28 (±0.06) | −118.98 (±6.03) | 99.17 (±3.63) | −19.81 (±4.72) |
| Compound 02 | −31.30 (±3.13) | −76.36 (±5.52) | 107.68 (±5.01) | −3.69 (±0.07) | −107.65 (±4.62) | 104.00 (±4.95) | −3.65 (±4.57) |
| Mesotrione | −41.97 (±1.89) | −74.11 (±3.13) | 91.38 (±3.01) | −3.64 (±0.05) | −116.08 (±3.72) | 87.74 (±2.99) | −28.34 (±3.18) |
ΔE.
Figure 11Inhibitor–residue interaction spectrum of complexes.
Figure 12The summary of structure–activity relationship.